Ipsen News | finanzen.ch

Ipsen Aktie VALOR 2348805 / ISIN FR0010259150

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

13.06.25	IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025 (GlobeNewswire)
12.06.25	Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
02.06.25	Ipsen S.A. - Initiation of the share buy-back program (GlobeNewswire)
27.01.23	Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. (Businesswire)
20.01.23	Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI (Businesswire)
09.01.23	Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases (Businesswire)
23.12.22	Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (Businesswire)
09.11.22	Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Businesswire)
27.10.22	Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance (Businesswire)
25.10.22	Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting (Businesswire)
12.08.22	Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology (Businesswire)
05.08.22	Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 (Businesswire)
03.08.22	Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer (Businesswire)
01.08.22	Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic (Businesswire)
29.06.22	Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission (Businesswire)
27.06.22	Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology (Businesswire)
14.04.17	Ipsen Appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	152.30	1.26 %	K V
ABB	47.98	0.76 %	K V
Sika	210.10	0.53 %	K V
UBS Group	26.22	0.46 %	K V
Holcim	93.50	0.43 %	K V
Alcon	70.26	-0.90 %	K V
Novartis	96.06	-1.13 %	K V
Givaudan	4’075.00	-1.19 %	K V
Roche Hldg G	265.90	-1.41 %	K V
Kuehne+Nagel Int	182.85	-1.96 %	K V